Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

ABSTRACT:

Background

A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency of drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab to paclitaxel and carboplatin administered every 3 weeks has shown efficacy in ovarian cancer. We proposed to determine whether dose-dense weekly paclitaxel and carboplatin would prolong progression-free survival as compared with paclitaxel and carboplatin administered every 3 weeks among patients receiving and those not receiving bevacizumab.

Methods

We prospectively stratified patients according to whether they elected to receive bevacizumab and then randomly assigned them to receive either paclitaxel, administered intravenously at a dose of 175 mg per square meter of body-surface area every 3 weeks, plus ca

SUBMITTER: Chan JK 

PROVIDER: S-EPMC5081077 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature